Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Int J Pharm ; 565: 20-32, 2019 Jun 30.
Artículo en Inglés | MEDLINE | ID: mdl-31051232

RESUMEN

The target of the current study is to formulate letrozole loaded nanoemulsion (LET-NE) for the direct nose to brain delivery to reduce peripheral effects of letrozole (LET). LET-NE is compared against intraperitoneally administered free LET in kainic acid (KA) induced status epilepticus (SE) in mice. LET loaded nanoemulsion (LET-NE) was prepared by aqueous microtitration method using Triacetin, Tween 80 and PEG-400 as the oil phase, surfactant, and co-surfactant. Nanoemulsion was studied for droplet size, polydispersity index (PDI), zeta potential, percentage transmittance, drug content, surface morphology. TEM images of developed formulation demonstrated spherical droplets with a mean diameter of 95.59 ±â€¯2.34 nm, PDI of 0.162 ±â€¯0.012 and zeta potential of -7.12 ±â€¯0.12 mV respectively. In in-vitro and ex-vivo drug release, LET-NE showed prolonged drug release profile as compared to suspension. SE was induced by KA (10 mg/kg, i.p.) in Swiss albino mice. Behavioral seizure monitoring, biochemical estimations, and histopathological examination were performed. The onset time of SE was significantly enhanced and % incidence of SE was reduced by intranasal administration of LET-NE as compared to KA and LET administered intraperitoneally. Biochemical estimations revealed that LET-NE effectively decreased levels of 17-ß estradiol while the levels of 5α-Dihydrotestosterone (5α-DHT) and 3α-androstanediol (3α-Diol) were significantly increased in the hippocampus. In cresyl violet staining LET-NE showed better protection of the hippocampus from neurotoxicity induced by KA as compared to LET. Also, in gamma scintigraphy of mouse brain, intranasal administration of nanoemulsion exhibited the presence of high concentration of LET. The study demonstrates the anticonvulsant and neuroprotective effect of LET-NE probably by inhibition of aromatization of testosterone into 17-ß estradiol, proconvulsant, and diverting the pathway into the synthesis of testosterone metabolites, 3α-Diol with known anticonvulsant and neuroprotective action. Brain targeting of LET-NE showed better anticonvulsant and neuroprotective action than LET.


Asunto(s)
Anticonvulsivantes/administración & dosificación , Inhibidores de la Aromatasa/administración & dosificación , Sistemas de Liberación de Medicamentos , Letrozol/administración & dosificación , Fármacos Neuroprotectores/administración & dosificación , Estado Epiléptico/tratamiento farmacológico , Animales , Anticonvulsivantes/química , Inhibidores de la Aromatasa/química , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Dihidrotestosterona/sangre , Diseño de Fármacos , Liberación de Fármacos , Emulsiones , Estradiol/sangre , Cabras , Ácido Kaínico , Letrozol/química , Masculino , Ratones , Mucosa Nasal/metabolismo , Fármacos Neuroprotectores/química , Polietilenglicoles/administración & dosificación , Polietilenglicoles/química , Polisorbatos/administración & dosificación , Polisorbatos/química , Estado Epiléptico/inducido químicamente , Triacetina/administración & dosificación , Triacetina/química
2.
J Pharm Sci ; 104(10): 3404-17, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26099467

RESUMEN

Achieving long-term drug release from polymer-based delivery systems continues to be a challenge particularly for the delivery of large hydrophilic molecules such as therapeutic antibodies and proteins. Here, we report on the utility of an in situ-forming and injectable polymer-solvent system for the long-term release of a model antibody fragment (Fab1). The delivery system was prepared by dispersing a spray-dried powder of Fab1 within poly(lactide-co-glycolide) (PLGA)-triacetin solution. The formulation viscosity was within the range 1.0 ± 0.3 Pa s but it was injectable through a 27G needle. The release profile of Fab1, measured in phosphate-buffered saline (PBS), showed a lag phase followed by sustained-release phase for close to 80 days. Antibody degradation during its residence within the depot was comparable to its degradation upon long-term incubation in PBS. On the basis of temporal changes in surface morphology, stiffness, and depot mass, a mechanism to account for the drug release profile has been proposed. The unprecedented release profile and retention of greater than 80% of antigen-binding capacity even after several weeks demonstrates that PLGA-triacetin solution could be a promising system for the long-term delivery of biologics.


Asunto(s)
Fragmentos de Inmunoglobulinas/química , Triacetina/química , Química Farmacéutica , Preparaciones de Acción Retardada , Desecación , Portadores de Fármacos , Sistemas de Liberación de Medicamentos , Estabilidad de Medicamentos , Concentración de Iones de Hidrógeno , Fragmentos Fab de Inmunoglobulinas/administración & dosificación , Fragmentos Fab de Inmunoglobulinas/química , Fragmentos de Inmunoglobulinas/administración & dosificación , Ácido Láctico/química , Tamaño de la Partícula , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Propiedades de Superficie , Triacetina/administración & dosificación , Viscosidad , Agua/análisis
3.
World J Gastroenterol ; 20(4): 1054-60, 2014 Jan 28.
Artículo en Inglés | MEDLINE | ID: mdl-24574778

RESUMEN

AIM: To examine the effect of intra-gastric triacetin on both upper gastrointestinal motility and proximal gastric tone in conscious dogs. METHODS: Three beagle dogs under sedation were surgically implanted with gastrocutaneous fistula in the gastric body and force transducers in the gastric antrum and duodenum. Beginning at week-2 after insertion, the animals were either fasted for 24 h or fed a liquid meal 2-3 h before the experiment. With the animals fully conscious, a polyethylene bag was inserted into the proximal stomach through the gastrocutaneous fistula, followed by 15 min of air inflation (minimal distending pressure of +2 mmHg) and then 20 mL of a low-, mid- or high-concentration triacetin solution (0.5%, 1.0% and 2.0%) or warm water (vehicle control). The proximal stomach receptive volume and gastric antral and duodenal contractions were measured over 10 min. The experiment was repeated twice per week over several months, with each animal receiving at least one infusion of the various triacetin solutions and the vehicle at different times. Intergroup differences were assessed by ANOVA and Bonferroni-Dunn post-hoc testing. RESULTS: Intra-gastric infusion of mid- and high-concentration triacetin induced an increase in the proximal stomach receptive volume, and the average increase induced by the high-concentration at 0-4 min after infusion was significantly greater than that induced by the vehicle control (62.4 ± 9.8 vs 18.4 ± 4.7, P < 0.01). The mid- and high-concentration triacetin also produced a temporary inhibition of the gastric antral contractions at 2 min after infusions; however, only the fasted group showed triacetin-induced antral contractile inhibition that was significantly greater than that in the vehicle control group (P < 0.05). In addition, only the fasted group showed a high-concentration triacetin-induced increase in duodenal contractions at 9-10 min that was significantly different from that in the vehicle control group (P < 0.05). CONCLUSION: Intra-gastric infusion of 1.0%-2.0% triacetin delays gastric emptying by increasing proximal stomach receptive volume, temporarily inhibiting gastric antral contractions and facilitating duodenal contractions.


Asunto(s)
Estado de Conciencia , Duodeno/efectos de los fármacos , Motilidad Gastrointestinal/efectos de los fármacos , Antro Pilórico/efectos de los fármacos , Triacetina/administración & dosificación , Animales , Perros , Relación Dosis-Respuesta a Droga , Duodeno/fisiología , Femenino , Vaciamiento Gástrico/efectos de los fármacos , Tránsito Gastrointestinal/efectos de los fármacos , Antro Pilórico/fisiología , Factores de Tiempo
4.
J Inherit Metab Dis ; 32(5): 640, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19685155

RESUMEN

Canavan disease (CD) is a fatal dysmyelinating genetic disorder associated with aspartoacylase deficiency, resulting in decreased brain acetate levels and reduced myelin lipid synthesis in the developing brain. Here we tested tolerability of a potent acetate precursor, glyceryl triacetate (GTA), at low doses in two infants diagnosed with CD, aged 8 and 13 months. Much higher doses of GTA were evaluated for toxicity in the tremor rat model of CD. GTA was given orally to the infants for up to 4.5 and 6 months, starting at 25 mg/kg twice daily, doubling the dose weekly until a maximum of 250 mg/kg reached. Wild-type and tremor rat pups were given GTA orally twice daily, initially at a dose of 4.2 g/kg from postnatal days 7 through 14, and at 5.8 g/kg from day 15 through 23, and thereafter in food (7.5%) and water (5%). At the end of the trial (approximately 90 to 120 days) sera and tissues from rats were analysed for changes in blood chemistry and histopathology. GTA treatment caused no detectable toxicity and the patients showed no deterioration in clinical status. In the high-dose animal studies, no significant differences in the mean blood chemistry values occurred between treated and untreated groups, and no lesions indicating toxicity were detectable in any of the tissues examined. Lack of GTA toxicity in two CD patients in low-dose trials, as well as in high-dose animal studies, suggests that higher, effective dose studies in human CD patients are warranted.


Asunto(s)
Enfermedad de Canavan/tratamiento farmacológico , Ratas , Temblor/tratamiento farmacológico , Triacetina/administración & dosificación , Triacetina/efectos adversos , Acetatos/administración & dosificación , Acetatos/efectos adversos , Acetatos/química , Administración Oral , Animales , Animales Recién Nacidos , Suplementos Dietéticos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Lactante , Masculino , Ratas Endogámicas WKY , Temblor/patología , Triglicéridos/química
5.
J Microencapsul ; 17(3): 343-62, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-10819422

RESUMEN

A novel method for in situ preparation of injectable biodegradable microspheres from the copolymer, poly(lactide-co-glycolide) (PLGA), without incorporating unacceptable organic solvents is described. The delivery system is a dispersion of PLGA microglobules ('premicrospheres' or 'embryonic microspheres') in an acceptable vehicle mixture (continuous phase) and whose integrity is maintained by the use of appropriate stabilizers. A solution of PLGA, triacetin, a model protein (cytochrome c), PEG 400, and Tween 80 (oil phase 1) is added dropwise with continuous homogenization to Miglyol 812-Span 80 solution (oil phase 2), thereby inducing phase separation (coacervation) of PLGA and forming PLGA microglobules (containing cytochrome c) dispersed in the continuous phase. This novel drug delivery system (NDDS) is a dispersion and has a viscous consistency, but is sufficiently syringeable. When injected, it comes in contact with water from an aqueous buffer or physiological fluid and, as a result, the microglobules harden to form solid matrix type microparticles entrapping cytochrome c (in situ formed microspheres). Cytochrome c is then released from these microspheres in a controlled fashion. The composition, rationale, and optimization of the NDDS are described here. Various formulation variables such as the PLGA concentration and type and the substitution of the continuous phase by a fresh oil phase 2 influenced the characteristics of this system. A preliminary investigation of the reproducibility and stability of the NDDS, as well as the physical stability of the encapsulated cytochrome c, revealed that these characteristics were not adversely affected.


Asunto(s)
Preparaciones de Acción Retardada , Portadores de Fármacos , Ácido Láctico , Microesferas , Ácido Poliglicólico , Polímeros , Antifúngicos/administración & dosificación , Rastreo Diferencial de Calorimetría , Dicroismo Circular , Grupo Citocromo c/administración & dosificación , Grupo Citocromo c/química , Composición de Medicamentos , Concentración de Iones de Hidrógeno , Inyecciones , Aceites , Tamaño de la Partícula , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polisorbatos , Triacetina/administración & dosificación
6.
J Nutr ; 125(5): 1267-73, 1995 May.
Artículo en Inglés | MEDLINE | ID: mdl-7738686

RESUMEN

Diets containing either triacetin (the water-soluble triglyceride of acetate) or long-chain triglycerides (LCT) were fed to rats for 30 d to determine the effect on body weight gain and adipose tissue cellularity. Male Sprague-Dawley rats were allowed free access to one of three diets: a control diet containing 5% of energy as fat or one of two experimental diets that contained 30% triglyceride (by energy). The source of the triglyceride in the two experimental groups was either 100% LCT or 95% triacetin + 5% LCT. Within the experimental groups receiving 30% fat, the source of dietary triglyceride (LCT vs. triacetin) did not affect total energy consumption. There were no significant differences in body weight at the onset of the study; however, animals fed 100% LCT weighed significantly more than the other two groups at the end of the study. In all three fat pads studied, animals fed triacetin had significantly lower pad mass than did animals fed LCT. Mean fat cell size was smaller in fat depots of animals fed short-chain triglyceride. Provision of dietary energy as the short-chain triglyceride triacetin in lieu of LCT resulted in lower weight gain and fat deposition. These data demonstrate the impact of dietary triglyceride composition on body weight regulation.


Asunto(s)
Adipocitos/citología , Grasas de la Dieta/farmacología , Metabolismo de los Lípidos , Triacetina/farmacología , Triglicéridos/farmacología , Adipocitos/efectos de los fármacos , Animales , Composición Corporal/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Recuento de Células , Grasas de la Dieta/administración & dosificación , Masculino , Ratas , Ratas Sprague-Dawley , Triacetina/administración & dosificación , Triglicéridos/administración & dosificación , Triglicéridos/química
7.
Clin Exp Obstet Gynecol ; 22(2): 105-10, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7781174

RESUMEN

OBJECTIVE: To compare two dosage regimens for the administration of vaginal prostaglandin gel in triacetin base for induction of labor. METHODS: Seventy subjects planned for elective induction of labor at term were randomized to treatment with PGE2 vaginal gel every 6 or 12 hours. The 6-hourly group received an initial dose of 1 mg, followed by 2 mg at 6 hour intervals for a maximum of two additional doses if not in active labor. The 12-hourly group had an initial dose of 2 mg followed by two additional doses at 12 hour intervals if not in active labor. RESULTS: Successful induction rate was higher in the 12-hourly as compared to 6-hourly gel regimen (100% vs. 91%, P > 0.05). Twelve hours after the initial dose, delivery occurred in 34% delivery had occurred in 57% and 37% respectively (P < 0.01). We found no difference in the induction-active labor interval (P > 0.05), and the induction-delivery interval (P > 0.05) between the two groups. Active labor followed a single dose of gel in 66% of the 12-hourly group compared to 40% of the 6-hourly group (P < 0.01). Syntocinon augmentation was needed in 6% of subjects in the 12-hourly group as compared to 26% in the 6-hourly group (P < 0.01). The cesarean section rate was similar in both groups. Uterine hyperstimulation occurred less frequently in the 12-hourly group (P < 0.05). The perinatal outcome was similar in both groups. CONCLUSIONS: The 12-hourly regimen was more effective than the 6-hourly regimen in initiating labor. The majority of the subjects in the 12 hourly group achieved labor following a single dose of gel. Induction delivery interval, however, was similar in both groups.


Asunto(s)
Dinoprostona/administración & dosificación , Trabajo de Parto Inducido , Triacetina/administración & dosificación , Adulto , Esquema de Medicación , Femenino , Humanos , Embarazo , Método Simple Ciego , Factores de Tiempo , Resultado del Tratamiento , Cremas, Espumas y Geles Vaginales
8.
Cutis ; 53(6): 313-6, 1994 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8070287

RESUMEN

Onychomycosis is one of the most common causes of nail disease and one of the hardest to treat among fungal infections. A double-blind, vehicle-controlled study has been conducted to evaluate the safety and efficacy of Fungoid Tincture (Pedinol Pharmacal, Inc), for the treatment of fungal infection of the toenails. Ten patients with distal subungual onychomycosis were treated for twelve months with topical Fungoid Tincture. Another ten patients with the same ailment were treated with the vehicle alone. Once a month, clinical and global evaluation of the target nail was done, in addition to trimming and debridement of the nails. After twelve months of treatment, 90 percent of patients applying Fungoid Tincture showed negative results on culture. There were minimal adverse effects.


Asunto(s)
Antifúngicos/uso terapéutico , Compuestos de Benzalconio/uso terapéutico , Cetilpiridinio/análogos & derivados , Dermatosis del Pie/tratamiento farmacológico , Dermatosis del Pie/microbiología , Onicomicosis/tratamiento farmacológico , Propionatos/uso terapéutico , Triacetina/uso terapéutico , Xilenos/uso terapéutico , Administración Cutánea , Adolescente , Adulto , Anciano , Antifúngicos/administración & dosificación , Antifúngicos/efectos adversos , Compuestos de Benzalconio/administración & dosificación , Compuestos de Benzalconio/efectos adversos , Cetilpiridinio/administración & dosificación , Cetilpiridinio/efectos adversos , Cetilpiridinio/uso terapéutico , Método Doble Ciego , Combinación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Vehículos Farmacéuticos , Propionatos/administración & dosificación , Propionatos/efectos adversos , Seguridad , Dedos del Pie , Triacetina/administración & dosificación , Triacetina/efectos adversos , Xilenos/administración & dosificación , Xilenos/efectos adversos
9.
J Nutr ; 122(9): 1823-9, 1992 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-1512631

RESUMEN

Little is known about the long-term metabolic effects of parenteral administration of short-chain triglycerides. These studies were undertaken to investigate triacetin, the water-soluble triglyceride of acetate when it is incorporated into nutritionally balanced total parenteral nutrition formulas. Male Sprague-Dawley rats (n = 22) were fed an isovolemic, isocaloric and isonitrogenous diet for 7 d. The lipid energy represented 30% of the nonprotein energy with short-chain triglycerides representing 0, 50 or 90% of the lipid energy. Plasma acetate concentration was determined as well as indicators of protein metabolism: daily and cumulative nitrogen balance, whole body leucine kinetics and rectus muscle and liver fractional protein synthetic rates. No overt toxic effects were observed at any point during the study. As the proportion of short-chain triglycerides in the diet increased from 0 to 50 or 90% of the lipid energy, cumulative nitrogen balance increased 50 or 120%, respectively (P less than 0.05). Whole-body and tissue leucine kinetics (determined during the last 2.5 h of the 7-d study) were unaffected by the lipid composition of the diet. Plasma acetate concentration was not significantly different among groups. These results indicate that incorporation of the short-chain triglyceride, triacetin, in nutritionally balanced total parenteral nutrition formulas improves nitrogen balance with no overt toxic effects. These data indicate that triacetin may have a future role as a parenteral nutrient, and that further studies of its use are warranted.


Asunto(s)
Nitrógeno/metabolismo , Nutrición Parenteral Total , Triacetina/farmacología , Acetatos/sangre , Ácido Acético , Animales , Ingestión de Energía , Cinética , Leucina/sangre , Leucina/metabolismo , Hígado/metabolismo , Masculino , Músculos/metabolismo , Consumo de Oxígeno , Biosíntesis de Proteínas , Ratas , Ratas Endogámicas , Triacetina/administración & dosificación
10.
Am J Clin Nutr ; 55(5): 1005-11, 1992 May.
Artículo en Inglés | MEDLINE | ID: mdl-1570794

RESUMEN

The effect of total parenteral nutrition with combinations of long-chain triglycerides (LCTs) and triacetin, the water-soluble triglyceride of acetate, on structural components of the gastrointestinal tract and protein metabolism was assessed in burned (30% body surface area) rats. Rats received isovolemic, isocaloric, and isonitrogenous diets that delivered 672 kJ.kg-1.d-1 (160 kcal.kg-1.d-1), 9.6 g amino acids.kg-1.d-1, and 30% nonprotein calories as 90% triacetin/10% LCTs, 50% triacetin/50% LCTs, or 100% LCTs for 7 d. Daily and cumulative nitrogen balances and whole-body leucine kinetics and fractional protein synthetic rates in rectus muscle and liver were determined on the last day of nutrition. DNA, protein, and total weight were determined in mucosal scrapings from segments of jejunum and colon. Plasma acetate concentrations were substantially higher in both triacetin groups. Parenteral nutrition with 50% triacetin and 50% LCTs promoted a positive nitrogen balance similar to that of 100% LCTs, increased protein in rectus muscle and liver, smaller and more numerous mucosal cells in jejunum and colon, and increased colonic mucosal weight compared with the other groups. Triacetin did not appreciably affect whole-body and tissue leucine kinetics. The equicaloric provision of triacetin and LCTs improved protein utilization and structural components of the small and large bowel and reduced the development of intestinal mucosal atrophy associated with conventional parenteral nutrition in burn injury.


Asunto(s)
Quemaduras/terapia , Mucosa Intestinal/patología , Nutrición Parenteral Total , Triacetina/uso terapéutico , Triglicéridos/administración & dosificación , Animales , Atrofia , ADN/análisis , Modelos Animales de Enfermedad , Ingestión de Energía , Metabolismo Energético , Fluidoterapia , Mucosa Intestinal/química , Leucina/sangre , Masculino , Nitrógeno/administración & dosificación , Nitrógeno/metabolismo , Proteínas/metabolismo , Distribución Aleatoria , Ratas , Ratas Endogámicas , Triacetina/administración & dosificación , Pérdida de Peso
11.
Cutis ; 49(5): 359-62, 1992 May.
Artículo en Inglés | MEDLINE | ID: mdl-1387844

RESUMEN

Onychomycosis is the most frequent cause of nail diseases. An open-label study has been conducted to evaluate the safety and efficacy of Fungoid Tincture, a topical antifungal agent approved by the Food and Drug Administration for the treatment of onychomycosis of the toes. Ten patients with culture-proven distal subungual onychomycosis were treated twice daily for twelve months with topical Fungoid Tincture. Another ten patients with the same condition were treated with the vehicle alone. At monthly intervals, the target nail was trimmed, the nail bed debrided, and global clinical assessment recorded. After twelve months of therapy, all patients applying Fungoid Tincture showed negative findings on fungal culture. The vehicle alone benefitted several patients, and may have antifungal activity. Adverse effects were minimal, with mild peeling occurring in seven patients and erythema noted in one.


Asunto(s)
Antifúngicos/uso terapéutico , Compuestos de Benzalconio/uso terapéutico , Cetilpiridinio/análogos & derivados , Onicomicosis/tratamiento farmacológico , Propionatos/uso terapéutico , Triacetina/uso terapéutico , Xilenos/uso terapéutico , Antifúngicos/administración & dosificación , Compuestos de Benzalconio/administración & dosificación , Cetilpiridinio/administración & dosificación , Cetilpiridinio/uso terapéutico , Combinación de Medicamentos , Femenino , Dermatosis del Pie/tratamiento farmacológico , Humanos , Masculino , Propionatos/administración & dosificación , Triacetina/administración & dosificación , Xilenos/administración & dosificación
12.
Am J Clin Nutr ; 53(4): 954-62, 1991 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1706907

RESUMEN

To determine whether short-chain triglycerides (SCTs, 1:1 triacetin:tributyrin, wt:wt) enhance intestinal adaptation in short-bowel syndrome (SBS), male Sprague-Dawley rats underwent 60% distal small-bowel resection with cecectomy and received either a chemically defined diet (CD) or a CD containing 40% of nonprotein energy as either medium-chain triglycerides (MCTs) or SCTs. After 12 d the SCT group had significantly increased jejunal mucosal weight compared with the MCT and CD groups and had significantly increased segment weight and mucosal protein compared with the CD group. In the colon the SCT group had significantly increased segment and mucosal weights and mucosal protein and DNA compared with both the MCT and CD groups. Body-weight change and measurements of serum ketones, albumin, glucose, and triglycerides revealed no significant differences among groups. SCTs improved jejunal and colonic adaptive growth and maintained comparable nutritional status in SBS when compared with CD alone or CD with MCTs.


Asunto(s)
Síndrome del Intestino Corto/dietoterapia , Triacetina/uso terapéutico , Triglicéridos/uso terapéutico , Ácido 3-Hidroxibutírico , Animales , Glucemia/metabolismo , Peso Corporal , Colon/metabolismo , Colon/patología , ADN/metabolismo , Hidroxibutiratos/sangre , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Yeyuno/metabolismo , Yeyuno/patología , Hígado/patología , Hígado/fisiopatología , Masculino , Nitrógeno/metabolismo , Tamaño de los Órganos , Páncreas/metabolismo , Páncreas/patología , ARN/metabolismo , Ratas , Ratas Endogámicas , Síndrome del Intestino Corto/metabolismo , Síndrome del Intestino Corto/patología , Triacetina/administración & dosificación , Triglicéridos/administración & dosificación
13.
JPEN J Parenter Enteral Nutr ; 15(1): 32-6, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1901105

RESUMEN

UNLABELLED: Triacetin, the water-soluble triglyceride of acetate, was infused in mongrel dogs at isocaloric (N = 6) or hypercaloric (approximately 1.5 REE, N = 7) rates in mongrel dogs for 3 hr. Ketone body and glucose production rates were quantified with [13C2] acetoacetate and [3H]glucose, respectively. Four additional animals were infused with glycerol to serve as controls for the hypercaloric triacetin infusion. Energy expenditure was determined in the isocaloric experiments. RESULTS: no evidence of acute toxicity was observed during triacetin infusion at either rate. Plasma acetate concentrations increased from basal levels to approximately 1 and approximately 13 mmol/liter in the isocaloric and hypercaloric experiments, respectively. Plasma lactate and pyruvate concentrations decreased dramatically after 30 min of both isocaloric and hypercaloric triacetin infusions. Glucose production rates did not increase in either group, but glucose clearance decreased significantly in both groups (p less than 0.05) over the last hour of triacetin infusion. Plasma ketone body concentrations increased from 1.4 to 3.5 and 1.8 to 13.5 mumol/kg.min, respectively, during isocaloric and hypercaloric triacetin infusion. Resting energy expenditure increased from 3.0 +/- 0.3 to 4.0 +/- 0.5 kcal/kg.hr during isocaloric triacetin infusion (p less than 0.05). These studies indicate that triacetin can be administered to dogs at high rates without overt toxicity. The decrease in glucose clearance may represent competition between carbohydrate (glucose) and lipid (acetate). Triacetin infusion resulted in significant increases in ketone body production and concentration. These preliminary data indicate that triacetin may have a future role as a parenteral nutrient, and that further studies of its use are warranted.


Asunto(s)
Nutrición Parenteral , Triacetina/administración & dosificación , Acetatos/sangre , Animales , Metabolismo Basal , Glucemia/análisis , Perros , Ácidos Grasos no Esterificados/sangre , Femenino , Glucagón/sangre , Infusiones Intravenosas , Insulina/sangre , Cuerpos Cetónicos/sangre , Lactatos/sangre , Piruvatos/sangre , Triacetina/toxicidad
14.
Geburtshilfe Frauenheilkd ; 47(3): 190-2, 1987 Mar.
Artículo en Alemán | MEDLINE | ID: mdl-3556308

RESUMEN

In an open randomized clinical study, 50 of 100 gravidae with a low Bishop score (less than or equal to 5) at term were treated with prostaglandin E2 (0.5 mg PGE2 in 2.5 ml Triacetin gel. Prepidil, intracervically) 12 hours before the indicated i.v. oxytocin induction. In 50 patients labor was induced intravenously without any pretreatment. In 46 of 50 pretreated women (92%) there was an increase in the Bishop score of at least three points, and of only two points in the remaining four. In the control group no significant increase in the Bishop score was measurable. Sixteen patients delivered within the first 12 hours after PGE2 gel administration, before oxytocin induction. Three women in the untreated control group also delivered during this pre-observation period. In 14 (64%) of 22 women in whom cervical priming with PGE2 was performed and 26 (57%) of 47 patients in whom it was not the first intravenous oxytocin induction was successful. The frequency of cesarean sections was 10% (n = 5) in the PGE2 gel group and 12% (n = 6) in the oxytocin group. The oxytocin dose needed to induce labor was significantly lower after cervical priming. No severe side effects were observed during and after PGE2 treatment, in either the mothers or the children.


Asunto(s)
Cuello del Útero/efectos de los fármacos , Trabajo de Parto Inducido/métodos , Oxitocina/administración & dosificación , Prostaglandinas E Sintéticas/uso terapéutico , Prostaglandinas E/uso terapéutico , Triacetina/administración & dosificación , Triacetina/uso terapéutico , Triglicéridos/administración & dosificación , Triglicéridos/uso terapéutico , Ensayos Clínicos como Asunto , Dinoprostona , Femenino , Geles/uso terapéutico , Humanos , Recién Nacido , Embarazo , Distribución Aleatoria
15.
Int J Gynaecol Obstet ; 24(4): 297-300, 1986 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-2878839

RESUMEN

A randomized study with a group of patients treated with a new ready-to-use triacetin-prostaglandin E2-gel compared to a non-treated group was conducted. The gel-treated group showed a distinct difference in cervical score after 12 h and ten patients were delivered during this period without further induction attempt compared to none in the control group. There was a significantly lower need for oxytocin stimulation in the treated group (P less than 0.0005), but there was no difference in the cesarean section rate or instrumental delivery rate. No side-effects were seen. This new gel seems effective and safe.


Asunto(s)
Cuello del Útero/efectos de los fármacos , Embarazo/efectos de los fármacos , Prostaglandinas E/farmacología , Triacetina/farmacología , Triglicéridos/farmacología , Contracción Uterina/efectos de los fármacos , Adulto , Dilatación , Dinoprostona , Femenino , Geles , Humanos , Prostaglandinas E/administración & dosificación , Distribución Aleatoria , Triacetina/administración & dosificación
16.
J Anim Sci ; 56(4): 867-75, 1983 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-6853383

RESUMEN

Twelve crossbred barrows from four litters (average initial body weight of 21 kg) were used to examine the relationship between acetate and glucose metabolism in pigs. The treatments were the addition of acetate in the form of triacetin to the basal diet at 0, 5 and 10% of the metabolizable energy intake. In the immediate postprandial period, the administered acetate decreased the venous plasma glucose concentration linearly (P less than .05) and increased linearly the venous plasma concentrations of lactate (P less than .01) and ketone bodies (P less than .001). There was a linear increase in the glycogen content of the liver (P less than .001), heart (P less than .001) and femoral muscle (P less than .01), as the level of acetate intake was increased. In the remote postprandial period (12 h after the last meal), glucose, which was considered to have been derived from hepatic glycogen storage, became the dominant blood metabolite in place of the acetate administered with the diet. This led to the reduction in hepatic production of endogenous acetate, arterial acetate concentration and in acetate utilization in the hind limb. Hepatic urea production was also decreased. Thus, there was a reciprocal change in acetate and glucose metabolism.


Asunto(s)
Acetatos/metabolismo , Glucosa/metabolismo , Porcinos/metabolismo , Ácido Acético , Animales , Glucemia/metabolismo , Peso Corporal , Dieta , Glucógeno/metabolismo , Cuerpos Cetónicos/sangre , Lactatos/sangre , Ácido Láctico , Glucógeno Hepático/metabolismo , Masculino , Porcinos/crecimiento & desarrollo , Triacetina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...